comparemela.com
  1. Home
  2. Live Updates
  3. Hennigsdorf - Breaking News

Latest Breaking News On - Hennigsdorf - Page 10 : comparemela.com

SphingoTec GmbH: Boditech Med and SphingoTec Close Global Licensing Agreement for Kidney Function Biomarker Proenkephalin A 119-159

Worldwide licensing agreement signed to develop and offer penKid as test on Boditech's fully automated immunoassay systems.The biomarker penKid adds diagnostic value and addresses current unmet needs in

Kangwon doSouth koreaRepublic of koreaKostenloser wertpapierhandelSphingotec gmbhSphingotec gmbhviewEui yul choiSphingotec gmbRuxandra lenzBoditech med incClin chem labBoditech medYul choiEarly biomarkerSeptic acute kidney injurySeptic shock

DB to work with Siemens and Alstom on next generation of high-speed trains

DB is looking ahead to design its high-speed train fleet for the 2030s by appointing Siemens and Alstom to develop concepts.

Saint ouenPoitou charentesAlbrecht neumannSiemens mobilityFrench railways

Munich neighbours sue to block construction of noisy Kita

Munich neighbours sue to block construction of noisy Kita
thelocal.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelocal.de Daily Mail and Mail on Sunday newspapers.

Baden wübergNordrhein westfalenFriso gentschWilliam kaneRiaan kritzingerFiona boydHow germany

Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming

/PRNewswire/ Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pantherna Therapeutics GmbH (CEO:Klaus Giese, Ph.D.,.

Kenji yasukawaKlaus gieseTaiji sawamotoBrandenburg innovationsforumAstellas pharma incResearch operationsDrug developmentAstellas pharmaPantherna therapeutics gmbhChief executive officerExecutive vice presidentApplied researchFocus areaFocus area approachTrend honorInnovative product

Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming

/PRNewswire/ Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pantherna Therapeutics GmbH (CEO:Klaus Giese, Ph.D.,.

Kenji yasukawaKlaus gieseTaiji sawamotoBrandenburg innovationsforumAstellas pharma incResearch operationsDrug developmentAstellas pharmaPantherna therapeutics gmbhChief executive officerExecutive vice presidentApplied researchFocus areaFocus area approachTrend honorInnovative product

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.